Outcome of platinum‑based chemotherapy for non‑small‑cell lung cancer patients with pleural dissemination detected during surgery

Kimura,Madoka; Murakami,Haruyasu; Naito,Tateaki; Kenmotsu,Hirotsugu; Taira,Tetsuhiko; Akamatsu,Hiroaki; Ono,Akira; Imai,Hisao; Takahashi,Toshiaki; Endo,Masahiro; Nakajima,Takashi; Ohde,Yasuhisa; Yamamoto,Nobuyuki

doi:10.3892/mco.2013.164

Outcome of platinum‑based chemotherapy for non‑small‑cell lung cancer patients with pleural dissemination detected during surgery

Authors:
- Madoka Kimura
- Haruyasu Murakami
- Tateaki Naito
- Hirotsugu Kenmotsu
- Tetsuhiko Taira
- Hiroaki Akamatsu
- Akira Ono
- Hisao Imai
- Toshiaki Takahashi
- Masahiro Endo
- Takashi Nakajima
- Yasuhisa Ohde
- Nobuyuki Yamamoto
View Affiliations

Affiliations: Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto‑gun, Shizuoka 411‑8777, Japan, Division of Diagnostic Radiology, Shizuoka Cancer Center, Sunto‑gun, Shizuoka 411‑8777, Japan, Division of Diagnostic Pathology, Shizuoka Cancer Center, Sunto‑gun, Shizuoka 411‑8777, Japan, Division of Thoracic Surgery, Shizuoka Cancer Center, Sunto‑gun, Shizuoka 411‑8777, Japan
Published online on: August 2, 2013 https://doi.org/10.3892/mco.2013.164
Pages: 949-952

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pleural dissemination detected by computed tomography (CT) is considered to be unfavorable for patients with non‑small‑cell lung cancer (NSCLC). However, the prognosis of NSCLC patients who are diagnosed with pleural dissemination at the time of surgery has yet to be adequately elucidated. To assess the outcomes of platinum‑based chemotherapy in NSCLC patients in whom pleural dissemination was detected during exploratory thoracotomy with or without a videoscope, the clinical records of NSCLC patients who were admitted to Shizuoka Cancer Center between September, 2002 and April, 2009 were reviewed. A total of 19 patients were included in this study, 12 males and 7 females, with a median age of 65 years. All patients were diagnosed with adenocarcinoma and 6 were epidermal growth factor receptor (EGFR) gene mutation‑positive. The median number of treatment cycles of first‑line platinum‑based chemotherapy was 4 (range, 1‑6 cycles) and the objective response rate was 21% [95% confidence interval (CI): 8.5‑43]. The median progression‑free and overall survival were 10.4 (95% CI: 6.3‑18.4) and 50.5 months (95% CI: 32.5‑98.0), respectively. Of the 18 patients with reported disease progression, 9 (50%) developed locoregional tumor progression. In conclusion, NSCLC patients in whom pleural dissemination is detected during surgery tend to have a favorable prognosis for survival. Systemic chemotherapy and additional local treatment may improve their clinical outcomes.

View Figures

View References

1.	Goldstraw P, Crowley J, Chansky K, et al International Association for the Study of Lung Cancer International Staging Committee: Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar
2.	Postmus PE, Brambilla E, Chansky K, et al International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2:686–693. 2007. View Article : Google Scholar
3.	Martini N: Surgical treatment of non-small cell lung cancer by stage. Semin Surg Oncol. 6:248–254. 1990. View Article : Google Scholar : PubMed/NCBI
4.	Ou SH and Zell JA: Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol. 3:216–227. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Lim E, Ali A, Theodorou P, Nicholson AG, Ladas G and Goldstraw P: Intraoperative pleural lavage cytology is an independent prognostic indicator for staging non-small cell lung cancer. J Thorac Cardiovasc Surg. 127:1113–1118. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Okamoto I, Yoshioka H, Morita S, et al: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar
9.	Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
10.	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
11.	Mordant P, Arame A, Foucault C, Dujon A, Le Pimpec Barthes F and Riquet M: Surgery for metastatic pleural extension of non-small-cell lung cancer. Eur J Cardiothorac Surg. 40:1444–1449. 2011.PubMed/NCBI
12.	Ichinose Y, Tsuchiya R, Koike T, et al Japan Clinical Oncology Group: The prognosis of patients with non-small cell lung cancer found to have carcinomatous pleuritis at thoracotomy. Surg Today. 30:1062–1066. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Ohta Y, Shimizu Y, Matsumoto I, Tamura M, Oda M and Watanabe G: Retrospective review of lung cancer patients with pleural dissemination after limited operations combined with parietal pleurectomy. J Surg Oncol. 91:237–242. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Rusch VW, Crowley J, Giroux DJ, et al International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2:603–612. 2007. View Article : Google Scholar
15.	Lim E, Clough R, Goldstraw P, et al International Pleural Lavage Cytology Collaborators: Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: an international individual patient data meta-analysis. J Thorac Cardiovasc Surg. 139:1441–1446. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Mitsudomi T, Morita S, Yatabe Y, et al West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
17.	Maemondo M, Inoue A, Kobayashi K, et al North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Fukuoka M, Wu YL, Thongprasert S, et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar
19.	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Yokoi K, Matsuguma H and Anraku M: Extrapleural pneumonectomy for lung cancer with carcinomatous pleuritis. J Thorac Cardiovasc Surg. 123:184–185. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Shimizu J, Oda M, Morita K, et al: Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination. J Surg Oncol. 61:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
22.	Ichinose Y, Tsuchiya R, Koike T, et al Japan Oncology Group: Prognosis of resected non-small cell lung cancer patients with carcinomatous pleuritis of minimal disease. Lung Cancer. 32:55–60. 2001. View Article : Google Scholar : PubMed/NCBI
23.	Riquet M, Foucault C and Souilamas F: Lung cancer with pleural dissemination: why not operation? Ann Thorac Surg. 74:1750author reply 1750. 2002. View Article : Google Scholar : PubMed/NCBI